A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...

Researchers estimate the number of people globally living with chronic obstructive pulmonary disease (COPD) will hit 600 million by 2050. There are certain risk factors for COPD, including obesity and ...

For patients with chronic obstructive pulmonary disease (COPD), the Global Initiative on Obstructive Lung Disease recommends long-term term pharmacologic and nonpharmacologic therapies based on each ...

Inflammation that develops in chronic obstructive pulmonary disorder stems from different causes. A new regulatory decision in Europe makes Sanofi and Regeneron Pharmaceuticals drug Dupixent the first ...

The anti-asthma and COPD segment grew 10 percent year-on-year in November, outpacing historical winter trends and marking its ...

Novel drug effective for asthma, COPD Reviewers are questioning the safety profile of combination umeclidinium/vilanterol after noting inconsistencies in data from ...

Angiogram of an MI (left) and a normal coronary artery (right) Inhaled anticholinergic agents, the most common treatment for chronic obstructive pulmonary disease (COPD), may increase the risk of ...

Roflumilast, a drug recently approved in the United States to treat severe chronic obstructive pulmonary disease (COPD), increases the production of a protein that causes inflammation, which possibly ...

The Food and Drug Administration on Friday rejected Sunovion Pharmaceuticals’ treatment for chronic obstructive pulmonary disease. The late-stage drug is intended to serve as a long-term treatment for ...